TNXP Stock Today (Nov. 25, 2025): Tonix Slips as Wall Street Weighs MDD IND Win, Tonmya Launch, and Dilution Risk
Tonix Pharmaceuticals shares fell 11% to close at $14.29 on Monday, despite receiving FDA clearance to advance its depression drug TNX-102 SL into Phase 2 trials. The stock sits near the bottom of its 52-week range after sharp volatility and recent expansion of its at-the-market stock offering program. Tonix recently launched Tonmya for fibromyalgia and reported $190.1 million in cash for Q3 2025.